Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
7.75
-0.36 (-4.44%)
At close: Aug 22, 2025, 4:00 PM
7.77
+0.02 (0.26%)
After-hours: Aug 22, 2025, 7:06 PM EDT
Mersana Therapeutics Employees
Mersana Therapeutics had 102 employees as of December 31, 2024. The number of employees decreased by 21 or -17.07% compared to the previous year.
Employees
102
Change (1Y)
-21
Growth (1Y)
-17.07%
Revenue / Employee
$340,873
Profits / Employee
-$725,853
Market Cap
38.68M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 102 | -21 | -17.07% |
Dec 31, 2023 | 123 | -105 | -46.05% |
Dec 31, 2022 | 228 | 59 | 34.91% |
Dec 31, 2021 | 169 | 59 | 53.64% |
Dec 31, 2020 | 110 | 27 | 32.53% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
MRSN News
- 9 days ago - Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results - GlobeNewsWire
- 16 days ago - Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025 - GlobeNewsWire
- 4 weeks ago - Mersana Therapeutics Announces 1-for-25 Reverse Stock Split - GlobeNewsWire
- 2 months ago - Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting - GlobeNewsWire
- 3 months ago - Mersana Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Mersana Therapeutics, Inc. (MRSN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results - GlobeNewsWire